EGFR mutated NSCLC-associated proteins covered by core CHMs and EGFR-TKIs

NIAID Data Ecosystem2026-05-10 收录

数据链接：

https://figshare.com/articles/dataset/EGFR_mutated_NSCLC-associated_proteins_covered_by_core_CHMs_and_EGFR-TKIs/31830958 数据链接链接失效反馈

官方服务：

资源简介：

EGFR mutated NSCLC-associated proteins covered by core CHMs and EGFR-TKIs

创建时间：

2026-03-22

DataSheet_1_The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial.docx

EGFR突变非小细胞肺癌治疗

药物安全性评估

BackgroundAs a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to research the therape

NIAID Data Ecosystem60

Supplementary Material for: Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma

EGFR突变非小细胞肺癌治疗

肿瘤生存预测

Background: First-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for the treatment of lung adenocarcinoma with an EGFR-sensitizing mutation, but resist

NIAID Data Ecosystem40

Table_1_Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, EGFR mutation, and high microsatellite instability.xlsx

肺肠型腺癌治疗

EGFR突变非小细胞肺癌治疗

BackgroundPulmonary enteric adenocarcinoma (PEAC) is a rare histological subtype of non-small-cell lung cancer (NSCLC) with a predominant (>50%) enteric differentiation component. The frequency of hig

NIAID Data Ecosystem10

Supplementary Tables – Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated NSCLC：A meta-analysis

EGFR突变非小细胞肺癌治疗

抗肿瘤药物疗效评估

Supplementary Table 1. Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated NSCLC：A meta-analysis The data available status for subgroup-a

NIAID Data Ecosystem50

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC

EGFR突变非小细胞肺癌治疗

免疫抑制治疗评估

First-line pembrolizumab plus chemotherapy has demonstrated durable, clinically meaningful survival benefits over 5 years, compared with chemotherapy alone, in pivotal clinical trials for patients wit

Figshare2025-10-17 更新10

EGFR mutated NSCLC-associated proteins covered by core CHMs and EGFR-TKIs

资源简介：

相关数据集